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THE EFFECTS OF THE PART D DOUGHNUT HOLE ON MEDICARE
PATIENTS WHO REQUIRE HIGH-COST MEDICATIONS
Esposito D1, Colby M2, Ball DE3, Garavaglia SB4, Meadows E3, Marciniak MD3
1Mathematica Policy Research, Inc, Princeton, NJ, USA, 2Mathematica Policy Research, Inc, 
Washington, DC, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Medco Health
Solutions, Inc., Franklin Lakes, NJ, USA
OBJECTIVES: To examine the effects of the Medicare Part D doughnut hole on
patients who require treatment with high-cost medications. METHODS: Using 2007
pharmacy claims from Medco Health Solutions, Inc., we used logistic regression 
analysis to examine the likelihood that patients’ spending reached the doughnut hole
($2400) or catastrophic coverage ($5451), or total drug spending equivalents, for
beneﬁ ciaries (enrolled for at least 6 months) with claims for cancer (N  32,625), 
osteoporosis (N  331,337), or rheumatoid arthritis (RA; N  5,712) medications. A 
comparison group with other chronic conditions (N  368,784) was matched to the
study population by age, gender, geography, chronic disease score, and low-income
subsidy (LIS) eligibility. Explanatory variables included plan type, coverage gap expo-
sure, disease type, and demographic characteristics. RESULTS: Compared to patients
with other chronic conditions (55%), patients with cancer (79%), RA (92%), or 
osteoporosis (58%) had higher odds of reaching the doughnut hole compared to 
patients with other chronic conditions (Odds Ratios [OR]  19.3, 32.1, and 2.1,
respectively, p  0.01 for all). A similar pattern of increased odds was observed for
reaching catastrophic coverage (OR cancer  5.2, RA  34.5, osteoporosis  1.4, p 
0.01). Compared with standard prescription drug plan (PDP) enrollees, enhanced PDP
enrollees were more (OR  1.1, p  0.01), Medicare Advantage enrollees were less 
(OR  0.8, p  0.01), and Retiree Drug Subsidy beneﬁ ciaries were as likely (OR 
0.99, p  0.88) to reach the doughnut hole. Relative to enrollees without a coverage 
gap, beneﬁ ciaries with one were less likely to reach $2400 in spending (OR  0.87, 
p  0.01); but were more likely to reach catastrophic coverage (OR  3.0, p  0.01). 
CONCLUSIONS: Regardless of drug plan, the vast majority of Medicare beneﬁ ciaries
in this study with cancer and RA, and most beneﬁ ciaries with osteoporosis faced large
out of pocket drug costs. For beneﬁ ciaries with these conditions, available prescription
coverage may not provide adequate protection from severe ﬁ nancial strain.
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RHEUMATOLOGIST INVOLVEMENT IN CARE OF PATIENTS WITH 
RHEUMATOID ARTHRITIS
Trivedi DN, Kreilick C, Rosenblatt LC
Bristol-Myers Squibb, Plainsboro, NJ, USA
OBJECTIVES: To determine physician specialties involved in rheumatoid arthritis 
(RA) diagnosis and follow-up care. METHODS: A retrospective analysis was per-
formed using PharMetrics” claims database. Patients newly diagnosed with RA (no
RA diagnosis claim in prior 12 months) were identiﬁ ed from April 1, 2005, to June
30, 2006, and were followed for 1 year. Patients were required to have at least one
additional RA diagnosis claim during the follow-up period and had to be continuously 
eligible 12 months before and after initial diagnosis date. Outcomes of interest were 
a) specialty of diagnosing physician b) percentage of patients receiving follow-up care
by a rheumatologist versus other specialties. RESULTS: Of newly diagnosed RA
patients (N  13,633), 34% were diagnosed by a rheumatologist, 13% by general/
family practice (GP), 13% by internal medicine (IM), and 30% by other specialties 
(11% were unknown). Of those diagnosed by a rheumatologist, 94% continued 
receiving rheumatologist care. Of those diagnosed by a GP, 57% continued to receive
care from GP and 13% received care from other specialty; of those diagnosed by IM,
65% continued to receive care from IM and 8% received care from other specialty.
Approximately 26% of those diagnosed by GP or IM received follow-up care from a 
rheumatologist. Irrespective of diagnosing physician specialty, the majority of patients
(52%) were not followed up by a rheumatologist. CONCLUSIONS: This study dem-
onstrates that the majority of RA patients are not diagnosed or followed by a rheu-
matologist. Future studies need to assess whether conﬁ rmation of RA diagnosis and 
follow-up by a rheumatologist, who has extensive training and experience in autoim-
mune disease, has an impact on patient outcomes.
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PHARMACY REFILL PATTERNS FOR SUBCUTANEOUS ANTI-TUMOR
NECROSIS FACTOR AGENTS USED IN THE TREATMENT OF
RHEUMATOID ARTHRITIS IN A MANAGED CARE SETTING
Carter C1, Tang B1, Changolkar A2, McKenzie RS1, Piech CT1
1Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2SOAL PharmaTech Solutions, 
LLC, Philadelphia, PA, USA
OBJECTIVES: To examine pharmacy reﬁ ll patterns of etanercept (ETA) and adalim-
umab (ADA) in the treatment of rheumatoid arthritis (RA) in a managed care popula-
tion. METHODS: Medical and pharmacy claims (January 1, 2000–December 31, 
2006) from a large managed care database were evaluated. Claims for all patients 
aged q18 years meeting the following criteria were included: qtwo diagnosis codes for
RA, no pharmacy or medical history of any biologic use for 6 months prior to anti-
TNF agent index date, anti-TNF agent index date occurring on or after the ﬁ rst RA 
diagnosis date, and q365 persistence days. Patients were excluded if they had a diag-
nosis of ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease, or ulcer-
ative colitis at anytime. Reﬁ ll patterns were examined by calculating the mean time 
(days) between each pharmacy reﬁ ll using NDC codes (actual reﬁ ll days) compared
to the mean days supplied on the claims (recommended reﬁ ll days). Results were 
reported for the ﬁ rst year following anti-TNF agent initiation. RESULTS: A total of 
1239 RA patients newly starting an anti-TNF agent were included (ETA  902, ADA 
 337). ETA patients were slightly younger than ADA patients (ETA  48.8 years, 
ADA  49.2 years, p  0.0001). There was no signiﬁ cant gender difference between
the two groups (ETA  77% female, ADA  75% female, p  0.29). Mean recom-
mended days supplied were 32 and 34 days for ETA and ADA, respectively. Mean
days between actual ETA pharmacy reﬁ lls were longer than recommended for 30%
of the reﬁ ll periods. Mean days between actual ADA pharmacy reﬁ lls were longer than
recommended for 28% of the reﬁ ll periods. CONCLUSIONS: Approximately one-
third of the actual pharmacy ﬁ lls for ETA and ADA had a longer time to patient reﬁ ll
compared to the recommended days supply, which may indicate noncompliance.
PMS57
PRIMARY CARE VISITS IN RHEUMATOID ARTHRITIS PATIENTS
RECEIVING INTRAVENOUS VERSUS SUBCUTAENOUS BIOLOGICS: A
RETROSPECTIVE CLAIMS DATABASE STUDY
Rosenblatt LC, Oza D
Bristol-Myers Squibb, Plainsboro, NJ, USA
OBJECTIVES: To determine whether patients diagnosed with rheumatoid arthritis
(RA) receiving intravenous (IV) biologics are more likely to visit a primary care physi-
cian (PCP) than patients receiving subcutaneous (SC) biologics for their RA treatment.
METHODS: A retrospective claims analysis was performed using PharMetrics Patient-
Centric Database. RA patients receiving biologic therapy were identiﬁ ed from January 
2003 to December 2006 and followed for at least 12 months after their ﬁ rst prescrip-
tion for IV or SC biologic (deﬁ ned as index date). Logistic regression analysis predict-
ing PCP visits was conducted, controlling for covariates, such as age, gender, region, 
payer type, provider type, Charlson Comorbidity Index, and speciﬁ c RA-related
comorbidities found to be signiﬁ cant in univariate analysis. RESULTS: There were 
1289 IV and 2543 SC patients included in the study. There were 73% females in the 
IV group vs. 71% in the SC group. Mean age was 58 years in the IV group and 53
years in SC group. The odds of having a PCP visit during follow-up period were 1.22
(95% CI-1.03, 1.44) times higher in the IV group as compared to the SC group, when
controlling for covariates such as age and comorbidities. CONCLUSIONS: RA
patients receiving IV biologics are more likely to maintain PCP visits compared to
patients receiving SC biologics. Future study needs to determine if more frequent
interaction with the health care system can lead to better general health care and the
likelihood of receiving holistic care in patients receiving IV biologics.
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FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS’ DISEASE
MANAGEMENT
Nasonov E1, Le Lay K2, Soldatov D3, Taieb C2
1Rheumatology Institute-Russian Federation, Moscou, Russia, 2Pierre Fabre, Boulogne, France, 
3Pierre Fabre Laboratories, Moscou, Russia
OBJECTIVES: Fibromyalgia syndrome (FMS) is an under-diagnosed disorder, of 
unknown etiology, which affects over 5% of patients in general medical practice; to 
describe Russian rheumatologists’ disease management of ﬁ bromyalgia patients. 
METHODS: The questionnaire was sent to a random sample of Russian practitioners, 
who were answering the same questionnaire as that used by French practitioners in
2003. RESULTS: Seventy-seven of the practitioners claimed that they prescribed a
medical treatment to their patients suffering from ﬁ bromyalgia: 40% prescribed anta-
lgics, 40% prescribed tricyclic antidepressants, 29% serotoninergic anti-depressants, 
30% hypnotics/sedatives, 8 % homeopathic treatments and a little over 1% morphine 
derivatives. 67% claimed that they prescribed extra treatments for their patients 
suffering from ﬁ bromyalgia: 23% prescribed antalgics, 20% prescribed tricyclic
antidepressants, 17% serotoninergic antidepressants, 24% hypnotics/sedatives, 
9% homeopathic treatments and less than 1% morphine derivatives. 82.6 % recom-
mended or prescribed other treatments to their ﬁ bromyalgic patients, namely: 36%
acupuncture, 56% physiotherapy, 14% hypnotherapy, 36% spa treatment, 3% oste-
opathy and 38% relaxation techniques. 91.8% of the doctors advised regular physical
exercise such as swimming and walking (71.9% and 65.6% respectively), with cycling 
being the activity least often advised, by 12.9% of the doctors. CONCLUSIONS:
Treatment for ﬁ bromyalgia must be multidisciplinary and multifactorial, its main 
objective being relieving the patient of their symptoms and allowing them to return 
to their professional and leisure activities – to which treatment of the condition by 
Russian practitioners is a testimony.
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
PSS1
META-ANALYSIS OF BIOLOGIC THERAPIES FOR THE TREATMENT OF
MODERATE TO SEVERE PSORIASIS
Hawkins NS1, Huntley A2, Eaton J2
1Oxford Outcomes (UK), Oxford, UK, 2Oxford Outcomes (UK), Oxford, Oxfordshire, UK
OBJECTIVES: To assess the comparative efﬁ cacy of biologics for the treatment of 
moderate to severe psoriasis. METHODS: A systematic literature review was con-
ducted to identify all randomized, controlled trials (until October 2008) evaluating 
the efﬁ cacy of approved biologics (adalimumab, efalizumab, etanercept, and inﬂ ix-
imab) for the treatment of moderate to severe psoriasis. As regulatory approval of 
ustekinumab in this indication is anticipated shortly, three Phase 3 trials of ustekinumab 
were also included in this review. A network meta-analysis (NMA) conducted on 
